Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial

Authors: Miguel R Abboud, Rodolfo D Cançado, Mariane De Montalembert, Wally R Smith, Hala Rimawi, Ersi Voskaridou, Birol Güvenç, Kenneth I Ataga, Deborah Keefe, Kai Grosch, Jimmy Watson, Evgeniya Reshetnyak, Michele L Nassin, Yvonne Dei-Adomakoh

Published: 2025-03-12

DOI: 10.1016/s2352-3026(24)00384-3

Source: Full article

---

Abstract

No abstract found.